NCT01754155

Brief Summary

The purpose of this study is to use Radiostereometric Analysis (RSA) and clinical outcome measures to evaluate early, post-operative implant stability, post-operative implant fixation, clinical performance, and in-vivo wear of the Zimmer® Continuum® Cup with vitamin E stabilized polyethylene.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 21, 2012

Completed
11 days until next milestone

Study Start

First participant enrolled

January 1, 2013

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

August 24, 2017

Status Verified

August 1, 2017

Enrollment Period

4.9 years

First QC Date

December 18, 2012

Last Update Submit

August 23, 2017

Conditions

Keywords

Vitamin EZimmerRSARadiostereometric Analysis

Outcome Measures

Primary Outcomes (7)

  • Assessing the Continuum® Cup for adequate fixation to the underlying bone as measured by migration and tilt

    2 years

  • Assessing the migration pattern of the Continuum® Cup

    2 years

  • Determining a correlation between radiolucent lines (RLLs) measured by Charnley-DeLee Zone Analyses and migration characteristics using RSA

    2 years

  • Determine if inducible displacement is indicative of adequate fixation

    2 years

  • Assess the health status and functional outcome of patients with the Continuum® Cup

    2 years

  • Assess the wear rate of the Vitamin E polyethylene with a ceramic femoral head

    2 years

  • Determine if the wear rate of the Vitamin E liner is the same in-vivo as it is in simulation testing

    2 years

Study Arms (1)

Vitamin E Polyethylene and RSA

OTHER

All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.

Radiation: RSA images

Interventions

RSA imagesRADIATION

All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.

Vitamin E Polyethylene and RSA

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Symptomatic osteoarthritis of the hip indicating surgical intervention
  • Scheduled to undergo an uncemented total hip arthroplasty (THA)
  • Patients between the ages of 18 and 65, inclusive
  • Ability to give informed consent
  • Patients will be available for follow-up for a minimum of 2 years after surgery

You may not qualify if:

  • Patients less than 18 years of age, or older than 65 years of age.
  • Post-traumatic arthritis in the affected hip
  • Rheumatoid arthritis in the affected hip
  • Hip dysplasia in the affected hip
  • Prior arthroplasty of the affected hip
  • Active or prior infection of the affected hip
  • Morbid obesity (BMI \> 35)
  • Medical condition precluding major surgery
  • Severe osteoporosis or osteopenia
  • Neuromuscular impairment
  • Patients with known allergy to metals
  • Pregnancy
  • Patients with compromised kidney function
  • Patient is immuno-suppressed
  • Patients that require a femoral head less than 32 mm or greater than 40mm.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central DuPage Hospital

Winfield, Illinois, 60190, United States

RECRUITING

Study Officials

  • Scott Sporer, MD

    Central DuPage Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2012

First Posted

December 21, 2012

Study Start

January 1, 2013

Primary Completion

December 1, 2017

Study Completion

December 1, 2018

Last Updated

August 24, 2017

Record last verified: 2017-08

Locations